Recombinant HLA Proteins
imusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more
T-cell
Peptide Binding Analysis
imusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read more
BMS and Cellares Enter $380m CAR T Cell Therapy Capacity & Supply Deal
Bristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read more
Nutcracker’s mRNA Drug Candidate for Prostate Cancer Effectively Targets CD3 T cells
Preclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read more
FDA Approves J&J and Bristol Myers Cell Therapies for Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read more
FDA Greenlights Iovance’s AMTAGVI™ as First T-cell Therapy for Solid Tumor Cancer
Iovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read more
AstraZeneca to Buy Gracell Advancing Cell Therapy Ambition
AstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read more
FDA Prioritises Review of Amgen’s Tarlatamab for Advanced Small Cell Lung Cancer
In a significant development for the fight against advanced small cell lung cancer (SCLC), the U.S. Food and Drug Administration
Read more
Boehringer Ingelheim Strengthens Immuno-oncology Portfolio with T3 Pharma Acquisition
Boehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read more
FDA Approves Bristol Myers’ Opdualag for Unresectable or Metastatic Melanoma
American multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read more